Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock - $0.001 par value
-
Shares outstanding
-
127,940,509
-
Total 13F shares
-
82,034,402
-
Share change
-
+1,875,781
-
Total reported value
-
$414,274,350
-
Price per share
-
$5.05
-
Number of holders
-
154
-
Value change
-
+$11,054,937
-
Number of buys
-
69
-
Number of sells
-
75
Institutional Holders of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) as of Q4 2025
As of 31 Dec 2025,
Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) was held by
154 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
82,034,402 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, Topline Capital Management, LLC, HHLR ADVISORS, LTD., Boston Partners, MILLENNIUM MANAGEMENT LLC, STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, DIMENSIONAL FUND ADVISORS LP, and BROWN CAPITAL MANAGEMENT LLC.
This page lists
154
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.